Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

Results showed that the CIC and flu vaccines generated “robust immune responses” across three flu strains (H1N1, H3N2 and B) ...

US biotech Novavax (Nasdaq: NVAX) has reported that its experimental combination COVID-19 and influenza vaccine generated ...

Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...

COVID-19-influenza combination (CIC) and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (TNIV) phase 3 ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

(NVAX) on Wednesday said that its COVID-19-Influenza combination and stand-alone Influenza vaccine candidates demonstrated a ...

The Gaithersburg, Md., biotechnology company said Wednesday that results of the initial cohort of vaccines showed both the Covid-19-influenza combination and flu-vaccine candidates induced immune ...

Novavax (NVAX) stock gains as the company reports promising Phase 3 trial results for its COVID-19-Influenza combo vaccine and stand-alone flu shot. Read more here.

In a report released today, Ed Mundy from Jefferies maintained a Buy rating on Diageo (DGEAF – Research Report), with a price target of £25.00. The company’s shares closed ye ...

While the US CDC recommends a six-month interval between JN.1 doses, it allows for a shorter gap of at least two months ...